The stock of Travere Therapeutics Inc (NASDAQ: TVTX) has increased by 3.29 when compared to last closing price of 17.13. Despite this, the company has experienced a 4.94% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-19 that Travere Therapeutics’ sparsentan received full FDA approval for IgA nephropathy, showing long-term kidney function preservation and significant market growth, with $35mn in 3Q24 revenues. Despite setbacks in FSGS trials, ongoing studies and FDA involvement suggest potential future approval, bolstered by proteinuria reduction as a validated surrogate endpoint. Financially, TVTX faces high operating expenses and cash runway concerns but aims to extend runway to 2028 through restructuring and secondary offerings.
Is It Worth Investing in Travere Therapeutics Inc (NASDAQ: TVTX) Right Now?
Company’s 36-month beta value is 0.70.Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TVTX is 85.74M, and currently, short sellers hold a 8.64% ratio of that floaft. The average trading volume of TVTX on December 26, 2024 was 1.66M shares.
TVTX’s Market Performance
The stock of Travere Therapeutics Inc (TVTX) has seen a 4.94% increase in the past week, with a -2.68% drop in the past month, and a 17.64% gain in the past quarter. The volatility ratio for the week is 4.28%, and the volatility levels for the past 30 days are at 4.08% for TVTX. The simple moving average for the last 20 days is -2.77% for TVTX stock, with a simple moving average of 56.36% for the last 200 days.
Analysts’ Opinion of TVTX
Many brokerage firms have already submitted their reports for TVTX stocks, with Wells Fargo repeating the rating for TVTX by listing it as a “Overweight.” The predicted price for TVTX in the upcoming period, according to Wells Fargo is $27 based on the research report published on October 21, 2024 of the current year 2024.
Guggenheim gave a rating of “Buy” to TVTX, setting the target price at $25 in the report published on September 09th of the current year.
TVTX Trading at -2.40% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.97% of loss for the given period.
Volatility was left at 4.08%, however, over the last 30 days, the volatility rate increased by 4.28%, as shares sank -8.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.19% lower at present.
During the last 5 trading sessions, TVTX rose by +3.68%, which changed the moving average for the period of 200-days by +125.55% in comparison to the 20-day moving average, which settled at $18.19. In addition, Travere Therapeutics Inc saw 96.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVTX starting from Calvin Sandra, who sale 12,090 shares at the price of $18.30 back on Nov 25 ’24. After this action, Calvin Sandra now owns 54,927 shares of Travere Therapeutics Inc, valued at $221,258 using the latest closing price.
Calvin Sandra, the Officer of Travere Therapeutics Inc, proposed sale 12,090 shares at $18.30 during a trade that took place back on Nov 25 ’24, which means that Calvin Sandra is holding shares at $221,258 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -1.69 for the present operating margin
- 0.84 for the gross margin
The net margin for Travere Therapeutics Inc stands at -1.73. The total capital return value is set at -1.09. Equity return is now at value -279.94, with -52.19 for asset returns.
Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 1.09 points at debt to capital in total, while cash flow to debt ratio is standing at -0.71. The debt to equity ratio resting at -12.6. The interest coverage ratio of the stock is -30.74.
Currently, EBITDA for the company is -326.25 million with net debt to EBITDA at -1.24. When we switch over and look at the enterprise to sales, we see a ratio of 9.36. The receivables turnover for the company is 8.08for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.71.
Conclusion
In a nutshell, Travere Therapeutics Inc (TVTX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
